CSL Ltd (CSJ MU) stock market data APIs
€121.884
0(0%)
as of October 20, 2025
Try our APIs with
free plan!
CSL Ltd Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for CSJ.MU.
Prev. Close
121.884
Open
121.884
High
121.884
Low
121.884
52 wk Range
109.26-177.7325
Market Cap
86 015 M
Dividends (Yield)
0.0082
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get CSL Ltd data using free add-ons & libraries
Get CSL Ltd Fundamental Data
CSL Ltd Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
CSL Ltd News
New
CSL Behring Signs Letter of Intent with pan-Canadian Pharmaceutical Alliance (pCPA) for Public Reimbursement of HEMGENIX® (etranacogene dezaparvovec), the First Gene Therapy for Hemophilia B
OTTAWA, Ontario, Oct. 6, 2025 /CNW/ -- CSL Behring Canada Inc., a business unit of global biopharma leader CSL, today announced that it has signed a Letter of Intent (LOI) with the pan-Canadian Pharm...
CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
FILSPARI® (sparsentan) suggested for IgA Nephropathy patients who are at risk of progressive kidney function loss ST. GALLEN, Switzerland, and SAN DIEGO, Sept. 26, 2025 /PRNewswire/ -- CSL Vifor and...
Declining Stock and Decent Financials: Is The Market Wrong About CSL Limited (ASX:CSL)?
It is hard to get excited after looking at CSL's (ASX:CSL) recent performance, when its stock has declined 18% over the past three months. But if you pay close attention, you might find that its key f...
VarmX Partners With CSL in a Strategic Collaboration and Option Agreement to Develop Novel Investigational Coagulation Treatment
Full funding of VMX-C001 Phase 3 trial, late-stage product development, manufacturing and pre-launch activities VarmX shareholders to receive initial $117m upfront and further potential milestone paym...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
